I finally finished the entire film, Uninformed Consent (great title), and I have a lot…
Subscribe to Updates
Get health & wellness insight updates.
Author: Janice Neuman
Xarelto, one of the newer generation of blood thinners, was approved by the FDA in 2011. It’s making news lately — and not for good reason. Lawsuits alleging rivaroxaban (Xarelto) harms — or even kills — keep piling up. Moreover, the FDA has concerns about the testing device used in the clinical trials that led to approval of the drug. If you’re taking this anticoagulant or one of its cousins — apixaban (Eliquis), edoxaban (Savaysa) and dabigatran (Pradaxa) — that are mainly prescribed to treat atrial fibrillation to prevent blood clots potentially causing a stroke, should you continue? While many…
MedShadow Foundation is an independent nonprofit health & wellness journalism organization focused on helping to protect lives from the side effects of medication and lower risk with alternative health options.
We help protect your life and the lives of your family by making sure you have the information you need to make informed decisions about the risks, benefits and alternatives to medicines.
Even though MedShadow is nonprofit, we refuse to accept support from pharmaceutical companies or medical device manufacturers. You can be sure that our information is free from the influence of pharmaceutical companies.
Symptoms & Concerns
MedShadow Foundation does not provide medical advice, diagnosis or treatment.
This site complies with the HONcode standard for trustworthy health information: verify here.
MedShadow Foundation is a registered 501(c)(3) non-profit organization. MedShadow does not accept advertising or contributions from pharmaceutical companies, medical device manufacturers or political action organizations.
Copyright © 2022, MedShadow Foundation. all rights reserved. Designed by Dante Steward